Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02640508 · ClinicalTrials.gov registry record · Phase 2
Eribulin and Lenvatinib in Advanced Solid Tumors
A Phase 2 study of Cancer and Solid Tumor, sponsored by Virginia G. Kaklamani.
- Completed
- Registry status
- Phase 2
- Development phase
- 29
- Enrollment target
- 1
- Study location
NCT02640508: Completed Phase 2 study of Cancer and Solid Tumor, sponsored by Virginia G. Kaklamani.
NCT02640508 is a Phase 2 study of Cancer and Solid Tumor that has completed, run by Virginia G. Kaklamani. The registered enrollment target is 29 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02640508, a Phase 2 study of Cancer and Solid Tumor, has completed, sponsored by Virginia G. Kaklamani.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 29 participants
- Enrollment target
- 1
- Study location
Study Summary
The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
Primary Outcome
Defined as the percentage of patients with best overall response of complete response (CR) or partial response (PR) as assessed by independent imaging review.
Conditions Studied
Interventions
- DRUG Eribulin
- DRUG Lenvatinib
Study Locations (1)
Texas
- Cancer Therapy and Research Center University of Texas Health Science Center San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-05 |
| Est. Completion | 2023-01-12 |
| Phase | Phase 2 |
What the finished NCT02640508 record still lists
NCT02640508 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 29 participants, a relatively small participant target, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which Eribulin is the first listed.
NCT02640508 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT02640508 about?
NCT02640508 is a clinical study titled "Eribulin and Lenvatinib in Advanced Solid Tumors". The overall purpose of this study is to determine the overall response rate, efficacy and safety of the combination of eribulin and Lenvatinib.
What is the current status of trial NCT02640508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 29 participants. The study started on 2016-05. Estimated completion is 2023-01-12.
What conditions does trial NCT02640508 study?
This clinical trial studies the following conditions: Cancer, Solid Tumor.
What interventions are being tested in trial NCT02640508?
The interventions under investigation include: Eribulin (DRUG), Lenvatinib (DRUG).
Who is sponsoring clinical trial NCT02640508?
This trial is sponsored by Virginia G. Kaklamani, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02640508 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02640508's enrollment target sits among peer trials
29 524th of 615 higher than 89 of 615 other Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
RECRUITING · Phase 2
-
CAncer TReatment INformed by the Molecular Tumor Board At Dartmouth
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Acupuncture for People Experiencing Period Loss Due to Chemotherapy
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02429557 · 29 participants · Phase 1
Hemodynamic Mechanisms of Abdominal Compression in the Treatment of Orthostatic Hypotension in Autonomic Failure
- NCT02568878 · 29 participants · Phase 3
Creatine for Depressed Male and Female Methamphetamine Users
- NCT03014401 · 29 participants · NA
The Effect of Adipose-Derived Stem Cells for Knee Osteoarthritis
- NCT03128996 · 29 participants · Phase 1
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia